CONSIDER PHARMACOKINETICS AND RESIDUAL EFFECTS

Continue to consider the residual effects when using immune-modifying agents

Remain mindful of the impact of prior therapies on your patient’s immune system1 :

  • Immunosuppressive effects may be delayed by months or years in some cases

Observed increases in blood cell counts from TYSABRI treatment were reversible upon discontinuation2 :

  • Observed increases in laboratory tests for circulating lymphocytes, monocytes, eosinophils, basophils, and nucleated red blood cells persisted during TYSABRI exposure, but were reversible, returning to baseline levels usually within 16 weeks after the last dose

Pharmacokinetics of TYSABRI2 :

  • Half-life (mean ± SD): 11 ± 4 days
  • Volume of distribution (mean ± SD): 5.7 ± 1.9 L
  • Clearance (mean ± SD):
    16 ± 5 mL/hour
  • Time to steady-state: ~24 weeks after every 4 weeks of dosing

Clinical decisions about when to initiate or discontinue therapy should be made at the discretion of the healthcare professional and patient.3